318,086 Shares in Immunome, Inc. $IMNM Purchased by Candriam S.C.A.

Candriam S.C.A. bought a new position in Immunome, Inc. (NASDAQ:IMNM) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 318,086 shares of the company’s stock, valued at approximately $2,958,000. Candriam S.C.A. owned approximately 0.37% of Immunome at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IMNM. MetLife Investment Management LLC increased its position in Immunome by 19.1% in the 1st quarter. MetLife Investment Management LLC now owns 42,411 shares of the company’s stock valued at $285,000 after acquiring an additional 6,792 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Immunome by 55.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 775,000 shares of the company’s stock valued at $5,216,000 after purchasing an additional 275,000 shares in the last quarter. Exome Asset Management LLC bought a new position in Immunome in the 1st quarter worth approximately $1,776,000. Charles Schwab Investment Management Inc. raised its position in shares of Immunome by 34.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 614,387 shares of the company’s stock worth $4,135,000 after acquiring an additional 157,135 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in Immunome in the second quarter valued at about $793,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Stock Performance

Shares of IMNM opened at $17.14 on Friday. The firm has a market cap of $1.57 billion, a P/E ratio of -5.81 and a beta of 1.96. Immunome, Inc. has a twelve month low of $5.15 and a twelve month high of $18.46. The firm’s 50 day moving average price is $13.54 and its two-hundred day moving average price is $10.79.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. On average, sell-side analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IMNM has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. The Goldman Sachs Group started coverage on Immunome in a research report on Monday, September 22nd. They set a “buy” rating and a $26.00 target price for the company. Craig Hallum initiated coverage on shares of Immunome in a research report on Friday, September 5th. They issued a “buy” rating and a $26.00 price target on the stock. Evercore ISI began coverage on shares of Immunome in a report on Friday, August 22nd. They issued an “outperform” rating and a $18.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $21.00 price objective on shares of Immunome in a research note on Friday, November 7th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Immunome presently has an average rating of “Moderate Buy” and a consensus price target of $23.44.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.